Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients

Nonsmall Cell Lung Cancer Clinical Trial

— PCRTALK  

Official title:

A Study to Compare the Performance of a qPCR-based Assay to Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH) in the Detection of Anaplastic Lymphoma Kinase (ALK) Fusion Mutations in Formalin Fixed Paraffin-embedded (FFPE) Tissue From Non-small Cell Lung Cancer (NSCLC) Patients.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02010047
• Other study ID #: PCRTALK
• Status: Completed
• Phase: N/A
• First received: December 5, 2013
• Last updated: August 4, 2017
• Start date: December 2013
• Est. completion date: August 18, 2015

Study information

• Verified date: July 2014
• Source: British Columbia Cancer Agency
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The anaplastic lymphoma kinase gene(ALK) is mutated approximately 5% of non-small cell lung cancers. Testing for this gene is important because there are drugs known as ALK inhibitors that have been shown to significantly delay the progression of ALK-mutated lung cancers. There are a number of ways to test for the presence of the ALK gene in lung cancer biopsy tissue. One method involves making slides and staining them to detect the ALK protein. This is called immunohistochemistry. Another method called fluorescence in situ hybridization(FISH)is used to detect rearrangements of the ALK gene associated with lung cancer. Although both these tests are widely used to test for ALK gene abnormalities, the techniques may not always find the ALK gene mutation because they are not sensitive enough or not enough cancer cells are present in the lung biopsy.

This study is being performed to determine if a technique called quantitation polymerase chain reaction (qPCR) is as accurate or better at finding the ALK gene mutation in lung cancer biopsy tissue.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 166
• Est. completion date: August 18, 2015
• Est. primary completion date: August 18, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• You have a confirmed diagnosis of non-squamous, non-endocrine non-small cell lung cancer.

• Your cancer biopsy has sufficient cancer cells to be tested for the (Epidermal Growth Factor Receptor (EGFR) mutation, the ALK fusion gene abnormality and the research ALK testing.

• Your lung cancer biopsy is determined not to have a mutation in the EGFR gene.

• You are 19 years old or older.

• You fully understand the study and give informed consent to participate as demonstrated by signing the consent.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Nonsmall Cell Lung Cancer

Intervention

Device:
• ALK qPCR assay
72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.

Locations

Country	Name	City	State
Canada	BC Cancer Agency-Abbotsford Centre	Abbotsford	British Columbia
Canada	BC Cancer Agency-Centre for the Southern Interior	Kelowna	British Columbia
Canada	Lions Gate Hospital	North Vancouver	British Columbia
Canada	BC Cancer Agency-Centre for the North	Prince George	British Columbia
Canada	BC Cancer Agency, Frase Valley Centre	Surrey	British Columbia
Canada	BC Cancer Agency, Vancouver Centre	Vancouver	British Columbia
Canada	BC Cancer Agency	Victoria	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
British Columbia Cancer Agency	Insight Genetics

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the true number of ALK positives and negatives of a qPCR assay for the detection in FFPE lung cancer biopsy specimens of ALK status in comparison with IHC and FISH ALK detection technologies.		Up to 24 weeks after the completing of enrollment of 72 ALK negative and 72 ALK positive tumor blocks
Secondary	The analysis of plasma and serum collected from those patients with ALK-positive NSCLC to assess the feasibility for the use of non-invasive sampling in the diagnosis and disease monitoring of lung cancer.		After completion of enrollemnt of 72 ALK postive tumor blocks.